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Abstract Rationale: Psychomotor stimulants can induce
psychotic states in humans that closely resemble those
observed in patients with idiopathic schizophrenia. At-
tentional and sensorimotor gating impairments are ob-
served in schizophrenic patients using the latent inhibition
(LI) and prepulse inhibition (PPI) behavioral assays,
respectively. Our previous studies demonstrated that after
4 days of withdrawal from a period of amphetamine
(AMPH) administration, animals exhibited disrupted LI
but normal PPI. Objective: The aim of the present study
was to test PPI in AMPH-withdrawn rats under experi-
mental conditions similar to those used to best demon-
strate locomotor sensitization following AMPH
withdrawal. Methods: We examined the effects on PPI
of (1) pairing drug injections with PPI test-associated
cues, (2) administration of a low-dose dopamine agonist
challenge and (3) testing following longer withdrawal
periods (23, 30, 60 days). Results: Although none of these
conditions revealed a disruption of PPI in AMPH-
withdrawn rats, we did observe that the acoustic startle
response was reduced during a restricted time period
following AMPH withdrawal. Similar to our previous
findings, AMPH-withdrawn animals showed disrupted LI
on day 16 of withdrawal and locomotor sensitization to a
challenge injection of AMPH after 62 days of withdrawal.
Conclusion: We conclude that the effects of repeated
AMPH on PPI are not modulated by the same experi-
mental parameters known to be important for eliciting
locomotor sensitization and that withdrawal from the
schedule of AMPH administration used in this study
models only specific cognitive dysfunctions linked to
schizophrenic symptoms, since LI was disrupted but PPI
was not affected.
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Introduction
Administration of amphetamine (AMPH) can induce
symptoms of psychosis in humans. This outcome is most
frequently associated with a chronic high-dose escalating
pattern of stimulant abuse (Davis and Schlemmer 1980;
Angrist 1994). Given that stimulant-induced psychosis in
humans closely resembles the psychosis observed in
patients with idiopathic schizophrenia (Ellinwood 1967;
Griffith et al. 1972; Snyder 1973), it has been suggested
that similar neural adaptations could be responsible for
the development of these two phenomena. It is well
known that repeated exposure to psychostimulants, like
AMPH or cocaine, induces psychomotor sensitization in
experimental animals. This phenomenon is indicated by a
progressive behavioral augmentation of responses (in-
creased locomotion, stereotypies) to drug challenge, as
well as an enhanced release of nucleus accumbens
dopamine (DA) following challenge AMPH administra-
tion (Robinson and Becker 1986; Segal and Kuczenski
1994). It has therefore been proposed that studies of the
neural bases of psychomotor stimulant sensitization might
yield insights into the biological mechanisms responsible
for the onset of schizophrenia (Kokkinidis and Anismann
1980; Robinson and Becker 1986; Lieberman et al. 1990).
Specifically, Lieberman and colleagues have suggested
that a process of endogenous sensitization, in which
schizophrenic patients exhibit enhanced DA release in
response to AMPH challenge, is a key element in the
pathology of the disease (Lieberman et al. 1990; Lieber-
man et al. 1997). Recent positron emission tomography
(PET) imaging studies examining competition for recep-
tor occupancy between endogenously released DA and
D2 receptor radioligand binding have established that not
only do schizophrenic patients show enhanced striatal DA
release in response to AMPH administration (i.e., a
sensitized response) but the DA response is positively
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correlated with the severity of their positive symptoms
(reviewed in Laruelle 2000). Thus, there is convincing
evidence for the involvement of sensitization processes in
the expression of the schizophrenic phenotype. A number
of studies have also established that, during the acute
phase of withdrawal from high-dose AMPH, animals
often exhibit depressive-like symptoms – in particular,
anhedonia as it is indexed by decreased sensitivity to
rewarding brain stimulation (Lin et al. 1999; Koob and Le
Moal 2001). However, the state of anhedonia during
AMPH withdrawal is typically very transient, persisting
for up to only 3–5 days following the last administration.
In comparison, behavioral sensitization can persist even
after prolonged periods of abstinence, a time course
which is perhaps more consistent with the long-term
adaptations typically associated with chronic mental
illness.
Two animal models believed to reflect cognitive/
attentional deficits typical of schizophrenic patients are
latent inhibition (LI) of classically conditioned respond-
ing and prepulse inhibition (PPI) of the startle response
(Weiner and Feldon 1997; Swerdlow et al. 2000). Both LI
and PPI are disrupted in schizophrenic patients, and these
deficits can be restored by neuroleptic treatment (Baruch
et al. 1988; Gray et al. 1992, 1995; Weiner and Feldon
1997; Braff et al. 2001). LI refers to the observation that
repeated exposure to a stimulus without consequence
comes to impede the formation of subsequent associations
with that stimulus (Lubow 1973). Our previous studies
have shown that LI is disrupted in rats pretreated with
escalating doses of AMPH during the first two weeks of
withdrawal (Murphy et al. 2001b). Moreover, the anti-
psychotic drugs haloperidol and clozapine restored LI in
AMPH-withdrawn rats (Russig et al. 2002). Thus, the LI
results during AMPH withdrawal are consistent with the
hypothesis, based on neuroimaging studies, that sensitized
levels of DA are associated with an animal model of
schizophrenic deficits.
PPI is the phenomenon whereby moderate-intensity
prepulse stimuli attenuate startle responses to subsequent
intense stimulation (Graham 1975; Braff et al. 1978;
Hoffman and Ison 1980). This phenomenon is thought to
result from the activation of central inhibitory mecha-
nisms that gate behavioral responses to ensuing stimuli
(Swerdlow et al. 1992; Taylor et al. 1995). Acute
administration of psychomotor stimulants such as AMPH,
apomorphine (APO) or selective D2 DA agonists disrupts
PPI, such that startle responses are less influenced by the
prepulse presentations (Mansbach et al. 1988; Peng et al.
1990; Bakshi et al. 1995; Caine et al. 1995; Taylor et al.
1995; Sills 1999). It is believed that PPI disruption may
index the sensorimotor gating deficit observed in schizo-
phrenic patients (Braff et al. 1978; Braff and Geyer 1990)
and that, consequently, the assessment of psychomotor
stimulant effects on PPI may be a valid animal model of
sensorimotor gating disturbances in schizophrenia (Braff
et al. 1992; Swerdlow et al. 1992, 1994). However,
previous studies from our laboratory showed no effect of
the escalating dose AMPH treatment on PPI tested on
day 4 of withdrawal (Murphy et al. 2001b). Given the
similarities in brain areas and cognitive functions impli-
cated in LI and PPI (Weiner and Feldon 1997; Swerdlow
et al. 2000) and the clear disruptive effects of withdrawal
from this escalating dose AMPH schedule on LI, it is
somewhat surprising that AMPH withdrawal does not also
affect PPI. The purpose of the present investigation was to
further explore this issue of PPI disruptibility during
AMPH withdrawal, by specifically examining the effects
on PPI of experimental conditions that are known to
maximize locomotor sensitization effects.
The role of contextual cues in psychostimulant-related
behavior has been extensively studied in sensitization
experiments (Robinson et al. 1998; Ohmori et al. 2000). It
has been shown that under certain experimental circum-
stances, sensitization to psychostimulants is only detected
when repeated drug administrations were previously
paired with specific contextual cues (Hinson and Poulos
1981; Drew and Glick 1988; Badiani et al. 1995;
Robinson et al. 1998). There is also direct evidence that
drug-conditioned cues disrupt sensorimotor gating. A
study with abstinent smokers indicated that a presentation
of smoking-associated stimuli reduced PPI (Hutchison et
al. 1999). Moreover, other studies have shown that PPI
was reduced during withdrawal from repeated DA agonist
treatment when drug administrations were repeatedly
paired with PPI testing (Zhang et al. 1998; Martin-Iverson
1999) whereas repeated psychostimulant treatment that
was not paired with PPI testing failed to result in PPI
reduction (Mansbach et al. 1988; Druhan et al. 1998;
Martinez et al. 1999; Byrnes et al. 2000; Adams et al.
2001). These studies suggest that PPI reduction following
repeated psychostimulant administration may, like loco-
motor sensitization, be context dependent such that
AMPH withdrawal-induced deficits in the PPI paradigm
might only be detected if a drug-related cue were present
during test. This hypothesis was tested in the present
study by measuring PPI in AMPH-withdrawn animals that
previously received drug injections paired with an
environment similar to that experienced during PPI
testing.
Locomotor sensitization is always measured following
the administration of a DA agonist challenge. Swerdlow
et al. (1995) previously demonstrated PPI disruption in
rats with lesions of the hippocampus and prefrontal cortex
following the administration of very low doses of the
direct DA agonist APO, whereas lesioned animals
receiving vehicle injections did not show reduced PPI.
In the present study, we sought to determine whether a
PPI disruption during AMPH withdrawal might be
similarly revealed following low-dose APO and AMPH
challenge injections.
Finally, it has been reported that sensitization of
locomotor behavior becomes more pronounced following
longer withdrawal periods (Paulson et al. 1991; Paulson
and Robinson 1995). That is, effects of AMPH pretreat-
ment that are not apparent during the first few days of
withdrawal have been found to emerge 1–2 weeks later.
Therefore, one objective of the present study was to
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investigate the time course of AMPH withdrawal effects
on PPI, to determine whether PPI disruption may become
evident only after an extended withdrawal period, similar
to behavioral sensitization.
The present study was designed to test the hypothesis
that effects of withdrawal from an escalating dosage
schedule of AMPH administration on PPI might be
revealed by experimental conditions similar to those used
to best demonstrate locomotor sensitization. These in-
clude administration of a DA agonist challenge, pairing of
drug administration with cues also associated with the PPI
testing protocol and testing after withdrawal intervals
longer than that used in a previous study (4 days). In
addition, to enable a direct comparison of LI and PPI
results in the same animals, we tested these animals for LI
following 16 days of withdrawal. Selected animals were
also tested for locomotor sensitization to a challenge
AMPH injection following 2 months of withdrawal.
Materials and methods
Animals
We used three batches of rats, 48 animals for experiment 1, 32
animals for experiment 2, and 32 animals for experiments 3 and 4
(Table 1). Male Wistar rats (Zur: WIST [HanIbm]; 250–350 g)
obtained from our in-house specific-pathogen-free (SPF) breeding
facility were used as subjects in these experiments. Animals were
housed individually in Macrolon type-III cages (482720 cm)
under reversed-cycle lighting (lights on 2100–0900 hours) in a
temperature- (21€1C) and humidity- (55€5%) controlled animal
facility. Food (Kliba 3430, Klibamhlen, Kaiseraugst, Switzerland)
and water were available ad libitum. All experiments were carried
out during the dark phase of the light/dark cycle and in agreement
with Swiss Cantonal regulations for animal experimentation.
Drugs and pretreatment procedure
d-Amphetamine sulfate (Sigma Chemical Company, St. Louis,
Mo., USA) was dissolved in a 0.9% NaCl solution to obtain
concentrations of 0.5, 1, 2, 3, 4 and 5 mg/ml AMPH (calculated as
the salt). Vehicle-treated groups received 0.9% NaCl solution. A
solution of 0.03 mg/kg APO was made by dissolving APO in 0.9%
NaCl with 0.1% ascorbic acid. All solutions were freshly prepared
and given in a volume of 1 ml/kg. AMPH and saline (SAL) were
injected intraperitoneally during the drug pretreatment period and
as a challenge administration, whereas APO and SAL administered
just prior to PPI testing were injected subcutaneously. During the
escalating-dose pretreatment schedule, animals received three
injections per day for six consecutive days, beginning with a
1 mg/kg dose and ending with doses of 5 mg/kg AMPH on the sixth
day of the cycle. The control group received injections of SAL
(0.9%) according to the same schedule. The dosing parameters are
summarized in Table 2.
Apparatus
PPI apparatus
Testing was conducted in four ventilated startle chambers (SR-
LAB, San Diego Instruments, San Diego, Calif.), each containing a
transparent Plexiglas tube (diameter 8.2 cm, length 20 cm) mounted
on a Plexiglas frame. Noise bursts were presented via a speaker
mounted 24 cm above the tube. Motion inside the tube was detected
by a piezoelectric accelerometer below the frame. The amplitude of
the whole body startle to an acoustic pulse was defined as the
average of one-hundred and fifty 1-ms accelerometer readings
collected from pulse onset.
Two-way avoidance apparatus
Testing was conducted in four identical shuttle boxes (Coulbourn
Instruments, Allentown, Pa.; model E10–16TC), each set in a
ventilated, sound- and light-attenuating shell (model E10–20). The
internal dimensions of each chamber were 351721.5 cm. The
grid floor of each chamber was divided into two identical
compartments by an aluminum hurdle (17-cm long, 4-cm high).
The barrier was very thin to prevent animals from balancing on it,
thus avoiding shock. Foot shocks were supplied to the grid floor by
a constant direct current source (model E 13–14) and a scanner
(model E 13–13) set at 0.5-mA intensity. During the experimental
session, each chamber was illuminated by a diffuse light source
(house light), mounted 19 cm above the grid floor in the center of
Table 2 Escalating dose amphetamine injection schedule (drug
doses in mg/kg)
0900 hours 1500 hours 2100 hours
Day 1 1 2 3
Day 2 4 5 5
Days 3–6 5 5 5
Table 1 Treatment conditions and withdrawal periods for animals used in experiments 1–4. inj injection, PPI prepulse inhibition, LI latent
inhibition, SAL saline, AMPH amphetamine
Pretreatment Withdrawal day and test
Day 4 Day 5 Day 16 Day 23 Day 24 Day 30 Day 60 Day 62
Experiment 1 SAL PPI SAL/APO inj. LI test
SAL inj. + PPI + PPI
AMPH PPI
SAL inj. + PPI
SAL/tube SAL inj. + PPI
AMPH/tube SAL inj. + PPI
Experiment 2 SAL PPI SAL/AMPH
AMPH inj. + PPI
Experiments 3
and 4
SAL PPI PPI Locomotor
sensitization
AMPH
342
the side walls. The conditioned stimulus (CS) was a tone of 85 dB
produced by a speaker (model E 12–02) placed behind the shuttle
box on the floor of the shell.
Apparatus for detection of locomotor activity
Sixteen stations were used. Each station was a 25-cm wide  40-cm
long  40-cm high compartment contained within an individual
sound-attenuating wooden cabinet. One end wall of the compart-
ment, the device wall, consisted of wooden panels, whereas the
remaining walls were clear plastic. The device wall contained a
water bottle spout and an opening that provided access to powdered
chow in a feeding bin. A large drop-down door in the front wall of
the compartment allowed easy access to the animal. The floor of
each compartment was a black removable pan holding a thin layer
of dark, absorbent, autoclaved earth. The ceiling was open. A 4-W
lamp (Lampi, model number 5304), outside the compartment but
within the cabinet, was used to produce a light/dark cycle. Each
lamp was connected to an appliance timer (Migros type NL24MI).
A fan mounted on the wall of a cabinet provided ventilation. A
camera, centered approximately 49 cm above the compartment
floor, was mounted in the ceiling of each cabinet. The field of
vision of the camera included the entire area of the compartment in
which an animal could move, and images from this camera were
used to quantify activity. The stations were located in a well-
ventilated, temperature-, humidity- and sound-controlled room that
was used only for this experiment. The room could be illuminated
with red ceiling lights. The cameras from all the stations were
connected to a 16-channel multiplexer (Sony model YS-DX216CE)
located in an adjoining room, and the multiplexer was connected, in
turn, to a Dell Computer (OptiPlex GXpro with a Pentium Pro
Processor) running image analysis software. The software was a
custom-written Visual Basic Program (P. Schmid, Laboratory of
Behavioral Neuroscience ETH Zurich) that was based on a NIH
Image Analysis script. The software “grabbed” an image from each
station every second and compared this image pixel by pixel with
an image obtained the second before. Each white Wistar rat was
monitored against a darker background. The percentage of pixels
that went from dark to light or from light to dark from one second
to the next was quantified. This percentage provided a measure of
the magnitude of an animal’s displacement or “activity”. One-
second activity values ranged from 0% (no movement) to
approximately 7.5%. The multiplexed images from the 16 stations
could be taped simultaneously on a single videotape with a video
recorder (Sony model SVT-1000P), and the 16 images could be
viewed simultaneously on a single monitor.
Behavioral testing procedures
PPI procedure
A background noise level of 68 dB(A) was maintained throughout
each test session. A test session started with 5 min of acclimati-
zation, after which four startle pulses [30 ms, 120 dB(A)] were
presented. These four initial startle pulses served to achieve a
relatively stable level of startle reactivity for the remainder of the
test session, as the most rapid habituation of the startle reflex occurs
within the first few startle pulse presentations (Koch 1999). To
measure PPI, six blocks of 11 trials were then presented. The 11
trials of each block included: two “pulse-alone” trials, one
“prepulse followed by pulse” and one “prepulse-alone” trial for
each of four prepulse intensities and one “no-stimulus” trial. The
prepulses were broadband bursts of 20-ms duration and an intensity
of either 72, 76, 80 or 84 dB(A). Between prepulse offset and pulse
onset, there was a time interval of 80 ms. The different trial types
were presented pseudo-randomly with an inter-trial interval of 10–
20 s (average 15 s). Each complete test session lasted about 23 min.
The percentage PPI (%PPI) induced by each prepulse intensity was
calculated as: [100–(100startle amplitude on “prepulse followed
by pulse” trial)/(startle amplitude on “pulse-alone” trial)].
Active avoidance procedure
The LI procedure in the two-way active avoidance paradigm was
carried out over 3 days. Animals received two consecutive daily
sessions of preexposure to both the tone and the apparatus or only
to the apparatus, and a conditioning session on the third day.
Days 1–2: preexposure to the apparatus or apparatus/tone CS. The
preexposure sessions took place on day 14 and day 15 of
withdrawal. Each non-preexposed (NPE) animal was placed in
the shuttle box with the house light on for a period of 50 min. Each
preexposed (PE) rat received 50 presentations of the tone (mean
variable inter-stimulus interval =50 s [range 10–90 s], duration
10 s). A general evaluation of each animal’s activity level was
supplied by recording the total number of crossings during the
preexposure sessions.
Day 3: conditioning to the CS. On day 16 of withdrawal, all
animals were tested for conditioned active avoidance. Each animal
was placed into the shuttle box and received 100 avoidance trials on
a variable interval schedule of 50 s, ranging from 10 s to 90 s. Each
avoidance trial began with a 10-s tone followed by a 2-s, 0.5 mA
shock, the tone remaining on with the shock. If the rat crossed the
barrier to the opposite compartment during the tone, the stimulus
was terminated and no shock was delivered (avoidance response).
A crossing response during the shock terminated the tone and the
shock (escape response). If the rat failed to cross during the entire
tone-shock trial, the tone and the shock terminated after 12 s
(unfinished trial). As an additional measure of activity, we analyzed
the total number of inter-trial crossings.
Sensitization procedure
AMPH-induced locomotion was assessed in 16 test boxes and
testing was carried out in three stages. In the first stage, each rat
was placed in the apparatus (withdrawal day 61) and allowed to
remain there undisturbed for 14 h. On withdrawal day 62, rats were
removed from the apparatus and injected with 0.9% saline and
again placed into the apparatus for the second stage, consisting of
1 h free exploration. Rats were then injected with 0.5 mg/kg AMPH
and returned to the apparatus for 6 h free exploration. Activity
levels were monitored for the entire duration of each of the three
stages.
Experiment 1: effects of drug-conditioned cues
and AMPH withdrawal on PPI and LI
1.1. Forty-eight Wistar rats were separated into six experimental
groups (n=8 per group) in this experiment (Table 1). During
the drug pretreatment period, eight SAL and eight AMPH-
treated animals (SAL/tube and AMPH/tube groups) were
placed directly following each injection into transparent
plexiglas tubes (diameter 10.5 cm, length 28 cm) which were
similar to PPI restraint tubes, but larger in size. The tubes were
placed within normal home cages that did not contain sawdust.
Following each 20-min exposure to the tube, animals were
returned to their home cages. The remaining 32 animals were
returned to their home cages immediately following each
injection of SAL (n=16) or AMPH (n=16). Preliminary results
suggested that an injection of saline prior to testing reduced
PPI; therefore, we compared the effects of AMPH withdrawal
on PPI in animals which did (SAL/SAL and AMPH/SAL
groups) and did not (SAL and AMPH groups) receive a saline
injection prior to test. On day 4 of withdrawal from AMPH, all
animals were tested for PPI in four squads randomized for
drug pretreatment and the different cue conditions. The SAL/
SAL and the AMPH/SAL as well as the SAL/tube and the
AMPH/tube animals received a SAL injection (i.p.) 5 min
before PPI testing was conducted.
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1.2. All of the animals from experiment 1.1 were used for the APO
challenge PPI test on day 5 of withdrawal. Half of the animals
in each drug/cue condition received 0.03 mg/kg APO (s.c.)
and the other half received a SAL injection (s.c.) 5 min prior
to placement in the PPI apparatus (n=4 per group).
1.3. All animals were subsequently tested for LI in a two-way
active avoidance paradigm as described above. The two
preexposure sessions took place on day 14 and day 15 of
withdrawal, and the test session was conducted on day 16 of
withdrawal. PE and NPE groups were counterbalanced for all
previous treatments and testing conditions (n=12 per group).
Experiment 2: effects of AMPH withdrawal on the acoustic
startle response and PPI at 23–24 days of withdrawal,
with and without a 0.5-mg/kg AMPH challenge injection
2.1. Two groups of 16 animals each were pretreated with either
AMPH or SAL. Following each injection, all animals were
returned to their home cages. The effects of AMPH and SAL
pretreatment on PPI and the acoustic startle response were
assessed following 23 days of withdrawal. Animals did not
receive any injection treatments on the test day.
2.2. On withdrawal day 24, half of the animals of each pretreat-
ment group used in experiment 2.1 received an AMPH
challenge injection of 0.5 mg/kg (i.p.) 5 min before beginning
PPI/acoustic startle response testing (SAL/AMPH and AMPH/
AMPH groups, n=8 per group). The remaining half of the
animals received a SAL injection 5 min before the test (SAL/
SAL and AMPH/SAL groups, n=8 per group).
Experiment 3: effects of 30 days and 60 days withdrawal
from an escalating dosage schedule of AMPH
on the acoustic startle response and PPI
Two additional groups of 16 animals each were pretreated with
either AMPH or SAL. Following each injection, all animals were
returned to their home cages. All rats were tested for the acoustic
startle response and PPI, first on day 30 and then again on day 60 of
withdrawal. Animals did not receive any injection treatments on the
test days.
Experiment 4: AMPH sensitization of locomotor activity
At 61–62 days of withdrawal, 16 animals (8 SAL, 8 AMPH) from
experiment 3 were tested for locomotor sensitization. Locomotor
activity was measured during a baseline period of 14 h, over a 1-h
period following a SAL injection, and over a 6-h period following a
challenge injection of 0.5 mg/kg AMPH.
Data collection and analysis
For all experiments post-hoc comparisons were conducted using
Fisher’s protected least-significant difference test. Significant
differences were accepted at P<0.05. All statistical analyses were
performed with the StatView software program (Abacus Concepts,
Inc., Berkeley, Calif., 1992).
Experiment 1
The startle amplitude of the PPI test on day 4 of withdrawal was
analyzed using a 3216 analysis of variance (ANOVA) design
consisting of the factors of drug-related cue condition (none, SAL
injection, tube and SAL injection) and drug pretreatment (SAL,
AMPH) and a repeated-measurements factor of 16 pulse-alone
presentations. Mean %PPI was analyzed using a 324 ANOVA
design consisting of the same between-subjects factors and a
repeated-measurements factor of four prepulse intensities. The
ANOVAs used for the PPI test on withdrawal day 5 included an
additional between-subjects factor of APO (SAL, APO) treatment.
For the two preexposure sessions in the active avoidance shuttle
box, the total number of crossings was analyzed using a 222
ANOVA with two between-subjects factors of drug pretreatment
(AMPH, SAL) and preexposure (NPE, PE), and with two preex-
posure days as a within-subjects factor. For the active avoidance
conditioning session, the 100 avoidance trials were separated into
ten blocks of ten trials each. Percentage avoidance responses were
analyzed using a 2210 ANOVA consisting of between-subjects
main factors of drug pretreatment and preexposure and a repeated-
measurements factor of ten-trial blocks. Total numbers of inter-trial
crossings were analyzed as an index of activity level using the
between-subjects main factors of drug pretreatment and preexpo-
sure
Experiment 2
Analysis of the acoustic startle response and PPI on withdrawal
day 23 was similar to experiment 1 but with only one between-
subjects factor of drug treatment (SAL, AMPH). The analysis of
acoustic startle and PPI on withdrawal day 24 also included a
between-subjects factor of drug challenge (AMPH, SAL).
Experiment 3
Acoustic startle response and PPI on withdrawal day 30 and day 60
were analyzed similarly to in experiment 1 with a between-subjects
factor of drug pretreatment (AMPH, SAL).
Experiment 4
Locomotor activity data were analyzed using three separate two-
way ANOVAs for the no-drug baseline, saline and AMPH periods,
each consisting of a between-subjects factor of drug pretreatment
(SAL, AMPH) and a repeated-measurements factor of 28 blocks of
30 min (baseline period), 6 blocks of 10 min (SAL period) or 36
blocks of 10 min (AMPH period).
Results
Experiment 1: effects of drug-conditioned cues
and AMPH withdrawal on PPI and LI
Experiment 1.1: effects of 4 days AMPH withdrawal
and drug-conditioned cues on the acoustic startle
response and PPI
A significant habituation of the startle response was seen
over the 16 pulse-alone presentations in all groups (main
effect of trials: F15,630=8.42, P<0.0001). However, there
were no significant effects of either drug pretreatment or
cue condition (Fig. 1A, B, C). The mean %PPI as a
function of prepulse intensity in the six conditions is also
shown in Fig. 1D, E, F. The ANOVA yielded a significant
main effect of prepulse intensity (F3,126=83.77,
P<0.0001), reflecting a gradual increase in PPI as a
function of the intensity of the prepulse stimulus.
However, there were no significant main effects or
interactions involving the factors of drug pretreatment
or cue condition on %PPI.
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Experiment 1.2: effects of 5 days AMPH withdrawal,
drug-conditioned cues and a 0.03-mg/kg APO challenge
injection on the acoustic startle response and PPI
In experiment 1.1, no differences in PPI or acoustic startle
were seen between those groups that received an injection
prior to testing (SAL/SAL and AMPH/SAL groups) and
those that did not (SAL and AMPH groups). Because all
animals were to receive a SAL or APO injection before
the PPI test in experiment 1.2, we collapsed the injected
and non-injected control groups of experiment 1.1 to form
a new no-cue treatment category. We analyzed the data in
a 222 ANOVA design, including the factors of drug
pretreatment (SAL, AMPH), cue treatment (no treatment,
tube) and challenge treatment (SAL, APO).
Independent of any drug pretreatment or cue treatment,
the animals again showed habituation of the startle
response over the 16 pulse-alone presentations
(F15,600=11.72, P<0.0001, Fig. 2A–D) but no other
significant main effects or interactions. The mean %PPI
for all experimental groups is summarized in Fig. 2E–H.
PPI was clearly evident in all groups and characterized by
an increased amount of inhibition as a function of the
intensity of the prepulse stimulus (main effect of prepulse
intensity: F3,120=39.10, P<0.0001). The analysis also
revealed a significant main effect of cue treatment
(F1,40=4.54, P<0.05), reflecting increased PPI in the tube
animals relative to the no-cue animals. Administration of
0.03 mg/kg APO reduced PPI overall (main effect of APO
treatment: F1,40=22.82, P<0.0001). No other significant
main effects or interactions were detected. Thus, APO
was not more effective in reducing PPI in AMPH-
pretreated groups than in SAL-pretreated groups.
Experiment 1.3: effects of 16 days AMPH withdrawal
on LI in the two-way active avoidance paradigm
PE and NPE groups were counterbalanced for all previous
treatments. There were no significant main effects or
interactions including the factors of cue condition or prior
APO treatment on behaviors measured during either the
preexposure or conditioning sessions; therefore, the data
were analyzed in a 22 design including only the factors
of drug pretreatment (SAL, AMPH) and preexposure
(NPE, PE).
Preexposure sessions. A comparison of the total number
of crossings during the two preexposure sessions revealed
a near-significant tendency for greater activity on the first
preexposure day relative to the second day (F1,44=3.16,
P=0.08; 35.5€2.3 for session 1 versus 31.8€2.0 for
Fig. 1. A–C Startle responses
during 16 pulse-alone trials. D–
F Percentage prepulse inhibi-
tion (%PPI) measured in rats
previously treated with am-
phetamine (AMPH) or saline
(SAL) and assigned to one of
six experimental conditions.
Animals represented in A, B, D
and E were returned to the
home cage after each injection
during the pretreatment phase
and received either no injection
treatment on the test day (A, D;
AMPH and SAL groups) or a
saline injection before testing
(B, E; AMPH/SAL and SAL/
SAL groups). Animals repre-
sented in C and F received
AMPH and SAL injections
during the pretreatment phase
that were paired with placement
into restraint tubes similar to
those used during PPI/startle
testing and also received a
saline injection before testing
(AMPH/tube and SAL/tube
groups). %PPI was measured
using a range of prepulse in-
tensities (72, 76, 80 or 84 dB).
Testing was conducted on day 4
of withdrawal. Values are
means€SEM. n=8 per group
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session 2), suggesting habituation to the apparatus. There
were no significant outcomes involving the factors of
drug treatment or preexposure (data not shown).
Conditioning session. PE rats made generally fewer
avoidance responses than NPE animals, as reflected by
a significant main effect of preexposure (F1,44=7.86,
P<0.01). Our analysis also revealed a highly significant
effect of blocks (F9,396=54.12, P<0.0001) and a signifi-
cant interaction of preexposure  drug  blocks
(F9,396=2.19, P<0.05). As can be seen in Fig. 3, all
groups acquired the avoidance response; however, LI
(i.e., significantly reduced avoidance performance in PE
relative to NPE rats) was only seen in the SAL groups
(Fisher’s post-hoc: SAL NPE versus SAL PE, P=0.017;
AMPH NPE versus AMPH PE, P=0.187). LI was
disrupted in the AMPH-pretreated rats primarily due to
increased avoidance responses in the PE group. Finally,
an analysis performed on the total number of inter-trial
crossings made by animals during the test session
revealed no significant main effects or interactions
involving the factors of drug pretreatment or preexposure
(data not shown).
Experiment 2: effects of AMPH withdrawal on the acoustic
startle response and PPI at 23–24 days of withdrawal,
with and without a 0.5-mg/kg AMPH challenge injection
Experiment 2.1: effects of 23 days AMPH withdrawal on
the acoustic startle response and PPI. All groups showed
Fig. 2. A–D Startle responses
during 16 pulse-alone trials. E–
H Percentage prepulse inhibi-
tion (%PPI) measured in rats
previously treated with am-
phetamine (AMPH) or saline
(SAL) and assigned to one of
four experimental conditions.
Animals represented in A, B, E
and F were returned to the
home cage after each injection
during the pretreatment phase
and received either an injection
of SAL (A, E; SAL/SAL and
AMPH/SAL groups; n=8 per
group) or apomorphine (APO;
B, F; SAL/APO and AMPH/
APO groups; n=8 per group)
before testing. Animals repre-
sented in C, D, G and H
received AMPH and SAL in-
jections during the pretreatment
phase that were paired with
placement into restraint tubes
similar to those used during
PPI/startle testing, and received
either an injection of SAL (C,
G; SAL/tube/SAL and AMPH/
tube/SAL groups; n=4 per
group) or APO (D, H; SAL/
tube/APO and AMPH/tube/
APO groups; n=4 per group)
before testing. %PPI was mea-
sured using a range of prepulse
intensities (72, 76, 80, or
84 dB). Testing was conducted
on day 5 of withdrawal. Values
are means€SEM
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habituation of the startle response over the 16 pulse-alone
presentations (main effect of trials: F15,450=7.71,
P<0.0001; Fig. 4A). AMPH-pretreated animals exhibited
a reduced acoustic startle response compared with the
SAL control animals, as reflected by a significant main
effect of drug treatment (F1,30=6.49, P<0.05). ANOVA of
the PPI results yielded a significant main effect of
prepulse intensity (F3,90=63.43, P<0.0001; Fig. 4D), re-
flecting a gradual increase in PPI as a function of intensity
of the prepulse stimulus. However, there were no
significant main effects or interactions including the
factor of drug pretreatment on PPI.
Experiment 2.2: effects of 24 days AMPH withdrawal and
a 0.5-mg/kg AMPH challenge injection on the acoustic
startle response and PPI. A highly significant main effect
of 16 trials (F15,420=8.55, P<0.0001) reflected a habitu-
ation of the startle response over the 16 pulse-alone
presentations (Fig. 4B, C). There were no significant main
effects or interactions including the factors of drug
treatment or challenge treatment. PPI again increased
Fig. 4 A–C Startle responses
during 16 pulse-alone trials. D–
F Percentage prepulse inhibi-
tion (%PPI) in rats previously
treated with amphetamine
(AMPH) or saline (SAL). Ani-
mals were tested on withdrawal
day 23 (A, D; n=16 per group)
and then again on day 24 after a
challenge injection of either
SAL (B, E; n=8 per group) or
0.5 mg/kg AMPH (D, F; n=8
per group). %PPI was measured
using a range of prepulse in-
tensities (72, 76, 80 or 84 dB).
Values are means€SEM
Fig. 3 Percentage of avoidance responses made during a 100-trial
test of conditioned two-way active avoidance acquisition in rats
previously treated with either amphetamine (AMPH) or saline
(SAL) and preexposed to either the apparatus (NPE) or to the tone
and the apparatus (PE). Rats were tested 16 days after their last
injection. Values are means€SEM. n=12 per group
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gradually as a function of prepulse intensity (main effect
of prepulse intensity: F3,84=32.16, P<0.0001). No signif-
icant main effects or interactions were detected for the
factors of drug pretreatment or challenge treatment on PPI
(Fig. 4E, F).
Experiment 3: effects of 30 days and 60 days AMPH
withdrawal on the acoustic startle response and PPI
Withdrawal day 30. Habituation to the acoustic startle
response over the 16 pulse-alone presentations was seen
in both AMPH- and SAL-treated animals (main effect of
trials: F15,450=4.65, P<0.0001, Fig. 5A). The startle
response was reduced following 30 days of AMPH
withdrawal, as reflected by a main effect of drug
pretreatment (F1,30=6.14, P<0.05). %PPI increased grad-
ually as a function of prepulse intensity (main effect of
prepulse intensity: F3,90=49.51, P<0.0001). However, PPI
did not differ between AMPH- and SAL-pretreated
animals, as supported by an absence of significant main
effects or interactions including the factor of drug
pretreatment (Fig. 5C).
Withdrawal day 60. During the 16 pulse-alone presenta-
tions, the acoustic startle response again appeared to
habituate over trials in both AMPH-pretreated and SAL
control rats, as reflected by a significant main effect of
trials (F15,450=4.49, P<0.0001). In contrast to our findings
at 30 days of withdrawal, however, AMPH and SAL
groups showed similar degrees of startle responding
(Fig. 5B). %PPI increased as a function of prepulse
intensity, as supported by a significant main factor of
prepulse intensity (F3,90=42.57, P<0.0001). Similar to our
results at 30 days of withdrawal, PPI did not differ
between AMPH and SAL groups, as supported by an
absence of significant main effects or interactions
including the factor of drug pretreatment (Fig. 5D).
Experiment 4: AMPH sensitization of locomotor activity
Sixteen of the animals from experiment 3 were tested on
days 61–62 of AMPH withdrawal for baseline levels of
locomotor activity and for locomotor responding to a
challenge injection of 0.5 mg/kg AMPH. Baseline
locomotor activity decreased over the 28 half-hour bins
(F27,378=40.30, P<0.0001) with no significant differences
between SAL- and AMPH-pretreated rats (not all data are
shown). This outcome reflected habituation to the appa-
ratus. As can be seen in Fig. 6, the last hour of the
habituation period was analyzed in blocks of 10 min, and
no significant effect of drug pretreatment was detected.
Animals showed an elevation of activity followed by a
rapid decrease in response to saline administration (main
effect of blocks: F5,70=31.83, P<0.0001; Fig. 6), with no
differences detected between SAL- and AMPH-pretreated
rats. Both AMPH and SAL groups showed an augmen-
tation of locomotor activity in response to a 0.5-mg/kg
AMPH challenge administration (Fig. 6). However,
AMPH-pretreated animals exhibited significantly en-
hanced locomotor activity during the first 40 min in
comparison with the SAL control group. This outcome
Fig. 5 A, B Startle responses
during 16 pulse-alone trials. C,
D Percentage prepulse inhibi-
tion (%PPI) in rats previously
treated with amphetamine
(AMPH) or saline (SAL). Ani-
mals were tested 30 days (A, C)
and 60 days (B, D) after their
last injection. %PPI was mea-
sured using a range of prepulse
intensities (72, 76, 80 or 84 dB).
Values are means€SEM. n=16
per group
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was supported by a significant interaction of drug
pretreatment  10-min bins during this period
(F35,490=1.86, P<0.01).
Discussion
The present study was designed to test the effects of
AMPH withdrawal on PPI using experimental conditions
known to be optimal for demonstrating behavioral
sensitization. Therefore, we measured PPI and the
acoustic startle response (1) after 4 days of withdrawal
in the presence and absence of a drug-conditioned
context, (2) following low-dose challenge injections of
the DA agonists APO and AMPH, and (3) at longer
withdrawal intervals. We found no effect of AMPH
withdrawal on PPI irrespective of these experimental
conditions. However, the acoustic startle response of
AMPH-treated rats was reduced on day 23 and day 30,
but not on day 4 and day 60 of withdrawal. Finally,
consistent with our previous findings (Murphy et al.
2001b; Russig et al. 2002), AMPH-pretreated rats showed
deficits in LI following 16 days of withdrawal and
pronounced sensitization of locomotor activity to an
AMPH challenge injection after 2 months of withdrawal.
Given that disrupted LI is an animal model of the
positive symptoms of schizophrenia, the LI reduction
found after a period of AMPH administration in this study
is consistent with the hypothesis that endogenous sensi-
tization of DA contributes to the expression of positive
schizophrenic symptoms. Importantly, the disruption of
LI in AMPH-withdrawn animals was almost entirely due
to the increased avoidance responses of the AMPH PE
relative to the SAL PE animals. We previously showed
that LI was disrupted following 4 days and 13 days of
withdrawal, and reduced but apparently beginning to
normalize after 28 days of withdrawal from the AMPH
schedule used in this study (Murphy et al. 2001b).
Moreover, the LI disruption induced by AMPH with-
drawal was restored by acute treatment with either
haloperidol or clozapine prior to avoidance conditioning
(Russig et al. 2002). In the present study, we have shown
that LI is significantly reduced after 16 days of with-
drawal as well, representing a modest extension of the
time course during which this effect is observed. Given
the reduced LI previously reported in schizophrenic
patients (Baruch et al. 1988; Gray et al. 1992, 1995),
the ability of repeated psychostimulant administration to
produce symptoms of psychosis (Davis and Schlemmer
1980; Angrist 1994), and the antipsychotic efficacy of
haloperidol and clozapine, we can speculate that AMPH
withdrawal-mediated disruptions of LI may reflect cog-
nitive processes that are linked to positive psychotic
symptoms.
We originally hypothesized that PPI might be similarly
eliminated during AMPH withdrawal. PPI disruption
immediately following a single AMPH administration has
been demonstrated in a number of studies (Mansbach et
al. 1988; Bakshi et al. 1995; Sills 1999; Geyer et al.
2001); however, previous investigations have failed to
show sensitization to the disruptive effects of repeated
AMPH on PPI, whether testing was conducted with or
without a challenge AMPH injection (Mansbach et al.
1988; Druhan et al.1998). In other studies, repeated
cocaine treatment similarly had no effect on PPI during
withdrawal and in fact prevented PPI disruption following
a challenge administration of the drug (Martinez et al.
1999; Byrnes et al. 2000; Adams et al. 2001). In contrast,
PPI was reduced by repeated DA agonist treatment when
the injections were paired with PPI testing (Zhang et al.
1998; Martin-Iverson 1999), suggesting that PPI reduc-
tions following repeated psychostimulant administration
might be revealed only in the presence of a drug-
associated context. Schulz and co-workers (2001) simi-
larly demonstrated that repeated dizocilpine (MK-801)
produced a sensitized disruption of PPI only when
repeatedly administered in the context of startle response
testing, and Gordon and Rosen (1999) showed that the
acoustic startle response is enhanced during cocaine
withdrawal only if cocaine injections had been paired
with prior exposure to the startle test environment. In the
present study, however, PPI was not disrupted during
AMPH withdrawal, either in animals presented with a
SAL injection cue prior to testing or in animals in which a
restraint tube context had been paired with AMPH
injections during pretreatment. The acoustic startle
response during the 16 pulse-alone trials was likewise
not affected by the SAL injection or restraint tube-AMPH
pairings. Our study differed from previous ones reporting
PPI reductions after repeated DA agonist treatment
(Zhang et al. 1998; Martin-Iverson 1999) in that we
exposed the rats during the pretreatment phase only to an
environment that was similar to the PPI tubes, whereas
the prior investigations paired DA agonist administrations
with both the context of PPI testing and exposure to
prepulses and startling stimuli. Our negative results in this
Fig. 6 Locomotor activity measured during an initial 16-h habit-
uation period (only the last hour shown), a 1-h period following an
injection of saline vehicle and a 6-h period following a challenge
injection of 0.5 mg/kg amphetamine. Testing was conducted 61–
62 days after the last injection in animals that had been pretreated
with either amphetamine (AMPH) or saline (SAL). Values are
means€SEM. n=8 per group
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regard suggest that the reported influence of drug-paired
startle testing in sensitizing PPI reductions is not strictly a
contextual association phenomenon. Rather, these effects
may result from processes more akin to fear-potentiated
startle (Davis 1986), whereby perhaps associations with
the sympathomimetic and/or anxiogenic properties of DA
agonists lead to either a potentiated or less-disruptible
startle response (i.e., reduced PPI).
Swerdlow and colleagues (1995) previously demon-
strated that PPI was reduced following an APO injection
in hippocampal lesioned rats which otherwise show no
PPI deficit. We similarly anticipated that administration
of low-dose APO and AMPH challenges prior to PPI
testing might uncover evidence of dysfunctional sensori-
motor gating. Indeed, in the present study, a single low
dose of 0.03 mg/kg APO disrupted PPI as has been shown
previously (Pouzet et al. 1999, Weiss et al. 1999, Geyer et
al. 2001). However, the effects of APO were similar in
SAL- and AMPH-pretreated rats, regardless of whether or
not animals had received injections paired with a PPI tube
context during the pretreatment phase. In addition,
administration of a 0.5-mg/kg AMPH challenge, a dose
which is not normally sufficient to reduce PPI (Kinney et
al. 1999; Feldon, unpublished observations), also did not
reveal a PPI disruption in AMPH-treated animals follow-
ing 24 days of withdrawal. As discussed above, these
results are consistent with those of previous investigations
in which startle testing was not paired with repeated DA
agonist administration (Mansbach et al. 1988; Druhan et
al. 1998). It is interesting to note that tube-PE animals
showed enhanced PPI during the APO challenge test
compared with the no-cue animals. This result indicates
that the tube-pretreatment was not totally ineffective in
influencing PPI; however, the enhancement effect of the
tube condition was not seen on day 4 (first PPI test) and
was not influenced by either drug pretreatment or
administration of an APO challenge injection. The reason
for this PPI enhancement effect is unclear at this time;
however, it is conceivable that after the initial PPI test,
tube animals’ increased familiarity with the PPI test
environment resulted in more selective attention to the
prepulse stimuli rather than to the context of the restraint
tube, thus increasing animals’ sensorimotor gating abil-
ities.
We also found that extending the time course of PPI
testing out to withdrawal day 60 did not reveal any
disruption due to AMPH withdrawal. However, the
acoustic startle response was significantly reduced on
withdrawal day 23 and day 30 in AMPH-pretreated
animals. In contrast, the acoustic startle response on day 4
was not significantly reduced in AMPH-pretreated ani-
mals, consistent with previous findings (Murphy et al.
2001b), and after 2 months the effect was again absent,
indicating that the startle reduction effect occurs within a
restricted time window. Withdrawal from another psy-
chostimulant drug, cocaine, also induces a reduction of
the acoustic startle response in rats (Gordon and Rosen
1999; Adams et al. 2001) and chronic cocaine users
similarly exhibit marked impairments in the acoustic
startle response (Efferen et al. 2000).
Since it is known that fear and anxiety increase the
startle reflex (Davis 1986) and a pleasant context
conversely attenuates startle amplitude (Lang et al.
1990; Koch 1999), it has been suggested that the startle
response measurement could be a useful index of an
animal’s emotional state (Marsh et al. 1973; Koch and
Schnitzler 1997). It seems unlikely that a positive hedonic
state develops that could be responsible for the reduction
in startle during AMPH withdrawal, given numerous
reports of negative affect during psychostimulant with-
drawal (Lin et al. 1999; Koob and Le Moal 2001). In fact,
we recently showed that animals receiving the schedule of
AMPH administration used in the present study showed
an enhanced conditioned fear response on day 4 of
withdrawal (Pezze et al.2002). The time course of this
increase in conditioned fear is likely to be a short-lived
effect, given that the symptoms of anxiety seen in both
psychostimulant-withdrawn rats and newly-abstinent hu-
man addicts are typically transient (Gawin 1991; Basso et
al. 1999). Therefore, if a transiently increased state of
anxiety independently potentiated the acoustic startle
response during the first week of withdrawal, it may have
effectively masked any reduction in startle present at that
time. It is possible then that the true time course of startle
reduction during AMPH withdrawal includes the entire
first month of withdrawal. The return of a normal startle
response on withdrawal day 60 suggests that normaliza-
tion of and/or compensation for the etiology of reduced
startle has taken place at this time. Given the fact that the
magnitude of the startle response in the absence of a CS
or a prepulse is sometimes viewed as a non-specific
behavioral parameter and that reduced startle during
AMPH withdrawal was only observed in two of four time
points in this study, and was not clearly seen on day 24
even in the same animals that showed the reduction on
day 23, it is difficult to gauge the true significance of this
effect at this time. Future studies will be needed to
determine the robustness of the startle reduction during
AMPH withdrawal as well as its biological underpin-
nings.
We predictably found evidence of locomotor sensiti-
zation to a 0.5-mg/kg AMPH challenge following
2 months of AMPH withdrawal; in a previous study, we
similarly demonstrated locomotor sensitization to a 1.0-
mg/kg AMPH challenge after 30 days of withdrawal from
the same AMPH injection schedule (Russig et al. 2001).
Increased DA release in the nucleus accumbens after an
AMPH challenge has been repeatedly found in sensitized
rats (Robinson and Becker 1986; but see Segal and
Kuczenski 1992) and numerous studies have shown that
both LI and PPI are disrupted by DA agonists (Swerdlow
et al. 1992; Weiner and Feldon 1997; Geyer et al. 2001).
However, basal levels of nucleus accumbens DA are
reportedly reduced or unchanged during AMPH with-
drawal (Rossetti et al. 1992; Segal and Kuczenski 1992;
Crippens et al. 1993). Our laboratory has in fact shown
that rats withdrawn from the AMPH schedule used in the
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present study showed no differences in basal DA levels,
but decreased DA efflux in the shell, and increased DA
efflux in the core of the nucleus accumbens during the
expression of a conditioned fear response (Pezze et al.
2002). If an enhanced nucleus accumbens core DA
response contributes in some manner to the disruption of
LI in AMPH-withdrawn rats, then apparently it is not
enough of a stimulus to elicit disrupted PPI in these
animals as well. However, reduced nucleus accumbens
shell DA responsiveness may contribute to startle reduc-
tion during AMPH withdrawal. In support of this idea,
blockade of DA receptors by acute administration of
risperidone or clozapine has been shown to decrease
startle amplitude (Johansson et al. 1995; Depoortere et al.
1997). Of course, other neurotransmitter systems may
also be involved in modulating the startle response during
AMPH withdrawal. In particular, there is strong evidence
for glutamatergic, noradrenergic and corticotropin-releas-
ing factor regulation of the acoustic startle response
(Davis 1986; Koch 1999).
Conclusions
To summarize, we report here that withdrawal from an
escalating dosage schedule of AMPH disrupted LI but left
PPI intact. Manipulations of the PPI testing environment
that were intended to simulate the experimental condi-
tions considered optimal for demonstrating behavioral
sensitization (contextual associations, presence of a DA
agonist challenge, later withdrawal time points for
testing) likewise did not reveal any increased sensitivity
of AMPH-withdrawn animals to PPI disruption. Such a
dissociation between LI and PPI has been shown previ-
ously following other behavioral and pharmacological
treatments (Wilkinson et al. 1994; Feldon et al. 2000;
Murphy et al. 2001a). The existence of this dissociation
may be due at least in part to the suggested involvement
of different brain regions in the mediation of LI and PPI.
LI has been linked primarily to activity within the nucleus
accumbens and hippocampus, whereas the regulation of
PPI is believed to occur in brain nuclei that extend from
the prefrontal cortex to the pontine tegmentum (Weiner
and Feldon 1997; Koch and Schnitzler 1997). Neverthe-
less, the attenuation of the startle response, which we
report here during AMPH withdrawal, is similar to
cocaine withdrawal effects on startle that have been
reported previously in both humans and in rodents
(Gordon and Rosen 1999; Efferen et al. 2000; Adams et
al. 2001). Further investigations will be needed to clarify
the neuronal mechanisms underlying this effect as well as
the functional significance of this reduction in startle to an
animal’s emotional state.
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